Polymorphism of IL‐10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2322
Abstract: Interleukin‐10 (IL‐10) and IL‐10 receptor (IL‐10R) single nucleotide polymorphisms have been implicated in the pathogenesis of many cancers. We investigated the influence of IL‐10 −592C/A, IL‐10RA I224V, and IL‐10RB K47E on the risk of developing… read more here.
Keywords: treated thalidomide; patients treated; prognosis; thalidomide bortezomib ... See more keywords